Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery.
dipeptidyl peptidase 4
lipids
liver
morbid obesity
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
31
10
2020
accepted:
29
12
2020
revised:
22
12
2020
pubmed:
5
2
2021
medline:
21
5
2021
entrez:
4
2
2021
Statut:
ppublish
Résumé
Dipeptidyl peptidase 4 (DPP4) is expressed and secreted by adipocytes. DPP4 induces insulin resistance independently of its effect on glucagon-like peptide 1, thus it is conceivable that DPP4 directly contributes to metabolic dysfunction in patients with morbid obesity. The aim of this study was to investigate the impact of weight loss induced by bariatric surgery on DPP4 activity, and whether these changes are associated with improvements in markers of metabolic dysfunction and fatty liver disease. We included 68 non-diabetic patients who underwent bariatric surgery. Serum DPP4 activity was measured using a fluorogenic substrate before and after surgery. Results: After a median follow-up period of 12 (IQR 11-17) months, median serum DPP4 activity decreased from 230 (IQR: 194-273) to 193 (164-252) pmol/min (p=0.012). The decrease in DPP4 activity was significantly correlated with decreases in BMI, improved cholesterol levels, reduced hepatic injury markers as well as improved post-prandial insulin sensitivity. After multivariable adjustment, ΔDPP4 activity remained significantly associated with Δcholesterol (beta=0.341, p=0.025), ΔLDL cholesterol (beta=0.350, p=0.019), Δgamma-glutamyltransferase (beta=0.323, p=0.040) and ΔMatsuda index (beta=-0.386, p=0.045). We demonstrated that weight loss induced by bariatric surgery results in decreased circulating DPP4 activity beyond the initial phase of weight loss. The associations between decreased DPP4 activity and improved cholesterol levels as well as hepatic injury markers point towards pleiotropic effects of DPP4 beyond glucose metabolism which warrant further investigation.
Identifiants
pubmed: 33538983
doi: 10.1007/s11695-020-05200-0
pii: 10.1007/s11695-020-05200-0
pmc: PMC8113172
doi:
Substances chimiques
Dipeptidyl Peptidase 4
EC 3.4.14.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2545-2550Références
Vishvanath L, Gupta RK. Contribution of adipogenesis to healthy adipose tissue expansion in obesity. J Clin Invest. 2019 Oct 1;129(10):4022–31.
pubmed: 31573549
pmcid: 6763245
doi: 10.1172/JCI129191
Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev. 2013 Jan;93(1):1–21.
pubmed: 23303904
doi: 10.1152/physrev.00017.2012
Liberale L, Bonaventura A, Vecchiè A, et al. The Role of Adipocytokines in Coronary Atherosclerosis. Curr Atheroscler Rep. 2017 Feb;19(2):10.
pubmed: 28185154
doi: 10.1007/s11883-017-0644-3
Satish M, Saxena SK, Adipokine Dysregulation ADK. Insulin Resistance with Atherosclerotic Vascular Disease: Metabolic Syndrome or Independent Sequelae? J Cardiovasc Transl Res. 2019 Oct;12(5):415–24.
pubmed: 30835048
pmcid: 6728239
doi: 10.1007/s12265-019-09879-0
Kumari R, Kumar S, Kant R. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr. 2019 Jul;13(4):2409–17.
pubmed: 31405652
doi: 10.1016/j.dsx.2019.06.005
Nargis T, Chakrabarti P. Significance of circulatory DPP4 activity in metabolic diseases. IUBMB Life. 2018 Feb;70(2):112–9.
pubmed: 29331088
doi: 10.1002/iub.1709
Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011 Jul;60(7):1917–25.
pubmed: 21593202
pmcid: 3121429
doi: 10.2337/db10-1707
Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993 Jun 15;214(3):829–35.
pubmed: 8100523
doi: 10.1111/j.1432-1033.1993.tb17986.x
Baumeier C, Schlüter L, Saussenthaler S, et al. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Mol Metab. 2017 Oct;6(10):1254–63.
pubmed: 29031724
pmcid: 5641684
doi: 10.1016/j.molmet.2017.07.016
Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Nov;16(11):642–53.
pubmed: 32929230
doi: 10.1038/s41574-020-0399-8
Madadi F, Jawad R, Mousati I, et al. Remission of Type 2 Diabetes and Sleeve Gastrectomy in Morbid Obesity: a Comparative Systematic Review and Meta-analysis. Obes Surg. 2019 Dec;29(12):4066–76.
pubmed: 31655953
doi: 10.1007/s11695-019-04199-3
Han Y, Jia Y, Wang H, et al. Comparative analysis of weight loss and resolution of comorbidities between laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: A systematic review and meta-analysis based on 18 studies. Int J Surg. 2020 Apr;76:101–10.
pubmed: 32151750
doi: 10.1016/j.ijsu.2020.02.035
Docherty NG, Le Roux CW. Physiological adaptations following Roux-en-Y gastric bypass and the identification of targets for bariatric mimetic pharmacotherapy. Curr Opin Pharmacol. 2015 Dec;25:23–9.
pubmed: 26496012
doi: 10.1016/j.coph.2015.09.012
American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S14–31.
doi: 10.2337/dc20-S002
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412–9.
pubmed: 3899825
doi: 10.1007/BF00280883
Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sep;22(9):1462–70.
pubmed: 10480510
doi: 10.2337/diacare.22.9.1462
Merlotti C, Ceriani V, Morabito A, et al. Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis. Int J Obes. 2017 May;41(5):672–82.
doi: 10.1038/ijo.2017.31
Alam ML, Van der Schueren BJ, Ahren B, et al. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab. 2011 Apr;13(4):378–81.
pubmed: 21210936
pmcid: 3656488
doi: 10.1111/j.1463-1326.2011.01358.x
Sarkar J, Nargis T, Tantia O, et al. Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients. Front Endocrinol. 2019 Jul 25;10:505.
doi: 10.3389/fendo.2019.00505
Müller MJ, Enderle J, Bosy-Westphal A. Changes in Energy Expenditure with Weight Gain and Weight Loss in Humans. Curr Obes Rep. 2016 Dec;5(4):413–23.
pubmed: 27739007
pmcid: 5097076
doi: 10.1007/s13679-016-0237-4
Jirapinyo P, Jin DX, Qazi T, et al. Meta-Analysis of GLP-1 After Roux-En-Y Gastric Bypass: Impact of Surgical Technique and Measurement Strategy. Obes Surg. 2018 Mar;28(3):615–26.
pubmed: 28871519
doi: 10.1007/s11695-017-2913-1
Hansen CF, Bueter M, Theis N, et al. Hypertrophy dependent doubling of L-cells in Roux-en-Y gastric bypass operated rats. PLoS One. 2013 Jun 11;8(6):e65696.
pubmed: 23776529
pmcid: 3679162
doi: 10.1371/journal.pone.0065696
Russel SM, Valle V, Spagni G, et al. Physiologic Mechanisms of Type II Diabetes Mellitus Remission Following Bariatric Surgery: a Meta-analysis and Clinical Implications. J Gastrointest Surg. 2020 Mar;24(3):728–41.
pubmed: 31898109
doi: 10.1007/s11605-019-04508-2
Qi L, Guo Y, Liu C-Q, et al. Effects of bariatric surgery on glycemic and lipid metabolism, surgical complication and quality of life in adolescents with obesity: a systematic review and meta-analysis. Surg Obes Relat Dis. 2017 Dec;13(12):2037–55.
pubmed: 29079384
doi: 10.1016/j.soard.2017.09.516
Blanchard C, Moreau F, Ayer A, et al. Roux-en-Y gastric bypass reduces plasma cholesterol in diet-induced obese mice by affecting trans-intestinal cholesterol excretion and intestinal cholesterol absorption. Int J Obes. 2018 Mar;42(3):552–60.
doi: 10.1038/ijo.2017.232
So SSY, Yeung CHC, Schooling CM, et al. Targeting bile acid metabolism in obesity reduction: A systematic review and meta-analysis. Obes Rev. 2020 Jul;21(7):e13017.
pubmed: 32187830
doi: 10.1111/obr.13017
Briand F, Thieblemont Q, Burcelin R, et al. Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. Diabetes Obes Metab. 2012 Jul;14(7):662–5.
pubmed: 22268579
doi: 10.1111/j.1463-1326.2012.01568.x
Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010 Mar;53(3):552–61.
pubmed: 19957161
doi: 10.1007/s00125-009-1611-5
Goto M, Furuta S, Yamashita S, et al. Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport. J Diabetes Investig. 2018 Nov;9(6):1261–9.
pubmed: 29754453
pmcid: 6215941
doi: 10.1111/jdi.12860
Aoki K, Ijima T, Kamiyama H, et al. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study. Expert Opin Pharmacother. 2015 Jun 22;16(12):1749–54.
pubmed: 26098722
doi: 10.1517/14656566.2015.1057120
Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology. 2015 Aug;149(2):379–88; quiz e15-6.
Stefan N, Häring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences. and treatment strategies. Lancet Diabetes Endocrinol. 2019 Apr;7(4):313–24.
pubmed: 30174213
doi: 10.1016/S2213-8587(18)30154-2
Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol. 2007 Oct;6(4):242–50.
pubmed: 18007554
doi: 10.1016/S1665-2681(19)31905-2
Miyazaki M, Kato M, Tanaka K, et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep. 2012 Mar;5(3):729–33.
pubmed: 22179204
Williams KH, Vieira De Ribeiro AJ, Prakoso E, et al. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study. J Diabetes. 2015 Nov;7(6):809–19.
pubmed: 25350950
doi: 10.1111/1753-0407.12237
Zheng T, Chen B, Yang L, et al. Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population. Metabolism. 2017 Aug;73:125–34.
pubmed: 28637594
doi: 10.1016/j.metabol.2017.04.012
Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011 Apr;60(4):1246–57.
pubmed: 21330637
pmcid: 3064098
doi: 10.2337/db10-1338
Ben-Shlomo S, Zvibel I, Shnell M, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011 Jun;54(6):1214–23.
pubmed: 21145820
doi: 10.1016/j.jhep.2010.09.032